Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Crowley

Showing results (21-30 of 178) with videos related to

Pageof 18
Sort By:
The New England Journal of Medicine|June 22, 2007
Allografting or autografting for myelomaFrits van Rhee, John Crowley, Bart Barlogie
Future Oncology (London, England)|April 12, 2017
End points and statistical considerations in immuno-oncology trials: impact on multiple myelomaAntje Hoering, Brian Durie, Hongwei Wang, et al.
Skeletal Radiology|April 10, 2020
Percutaneous thermal ablation for treatment of osteoid osteoma: a systematic review and analysisWill S Lindquester, John Crowley, C Matthew Hawkins
Clinical Lymphoma, Myeloma & Leukemia|April 2, 2011
Autologous stem cell transplantation as a care option in Waldenström's macroglobulinemiaSaad Usmani, Rachel Sexton, John Crowley, et al.
Annals of Hematology|December 15, 2010
Prognostic factor analyses of myeloma survival with intergroup trial S9321 (INT 0141): examining whether different variables govern different time segments of survivalBart Barlogie, Vanessa Bolejack, Michael Schell, et al.
The New England Journal of Medicine|July 8, 2005
Osteonecrosis of the jaw and bisphosphonatesBrian G M Durie, Michael Katz, John Crowley
Clinical Trials (London, England)|March 27, 2013
Early phase trial design for assessing several dose levels for toxicity and efficacy for targeted agentsAntje Hoering, Alan Mitchell, Michael LeBlanc, et al.
Kansas Journal of Medicine|October 5, 2022
Angioedema with Three Possible EtiologiesChancen Hall, David Petrie, John Crowley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2004
Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trialsBrian G M Durie, Joth Jacobson, Bart Barlogie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2009
Randomized phase II designsLarry Rubinstein, John Crowley, Percy Ivy, et al.
Pageof 18

Showing results (21-30 of 178) with videos related to

Sort By:
Pageof 18
The New England Journal of Medicine|June 22, 2007
Allografting or autografting for myelomaFrits van Rhee, John Crowley, Bart Barlogie
Future Oncology (London, England)|April 12, 2017
End points and statistical considerations in immuno-oncology trials: impact on multiple myelomaAntje Hoering, Brian Durie, Hongwei Wang, et al.
Skeletal Radiology|April 10, 2020
Percutaneous thermal ablation for treatment of osteoid osteoma: a systematic review and analysisWill S Lindquester, John Crowley, C Matthew Hawkins
Clinical Lymphoma, Myeloma & Leukemia|April 2, 2011
Autologous stem cell transplantation as a care option in Waldenström's macroglobulinemiaSaad Usmani, Rachel Sexton, John Crowley, et al.
Annals of Hematology|December 15, 2010
Prognostic factor analyses of myeloma survival with intergroup trial S9321 (INT 0141): examining whether different variables govern different time segments of survivalBart Barlogie, Vanessa Bolejack, Michael Schell, et al.
The New England Journal of Medicine|July 8, 2005
Osteonecrosis of the jaw and bisphosphonatesBrian G M Durie, Michael Katz, John Crowley
Clinical Trials (London, England)|March 27, 2013
Early phase trial design for assessing several dose levels for toxicity and efficacy for targeted agentsAntje Hoering, Alan Mitchell, Michael LeBlanc, et al.
Kansas Journal of Medicine|October 5, 2022
Angioedema with Three Possible EtiologiesChancen Hall, David Petrie, John Crowley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2004
Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trialsBrian G M Durie, Joth Jacobson, Bart Barlogie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2009
Randomized phase II designsLarry Rubinstein, John Crowley, Percy Ivy, et al.
Pageof 18